Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT04105413 Not yet recruiting - Sepses, Neonatal Clinical Trials

Early Diagnosis of Neonatal Sepsis

Start date: September 30, 2019
Phase:
Study type: Observational

Sepsis is defined as a systemic inflammatory response syndrome (SIRS) associated with infection diagnosed either on microbiologic cultures or strong clinical evidence of an infection.

NCT ID: NCT04105400 Not yet recruiting - Sepsis, Severe Clinical Trials

Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient

Start date: November 1, 2019
Phase:
Study type: Observational [Patient Registry]

correlation between procalcitonin levels and the severity of sepsis and it's possibility to be used as a prognostic marker in patients with sepsis and severe sepsis

NCT ID: NCT04041765 Not yet recruiting - Inflammation Clinical Trials

IgM-Enriched Immunoglobulin for Neonatal Sepsis

Start date: September 2019
Phase: Phase 3
Study type: Interventional

This study compares giving prophylactic IgM enriched Intravenous Immunoglobulin (IVIG) with placebo in 1 hour after birth, in neonates with risk factors of Early-Onset Neonatal Sepsis (EONS). In addition to the intervention, standard regimen antibiotics are also given within 1 hour. The IVIG is given for 3 days and primary and secondary outcomes will be collected. Risk factors are both from maternal and neonate origin.

NCT ID: NCT04015752 Not yet recruiting - Sepsis Clinical Trials

Sepsis in ICU:Causes and Outcomes of Sepsis in Diabetics Versus Non Diabetics in Assiut University Hospital

Start date: August 2019
Phase:
Study type: Observational

Clarify different causes of sepsis in patients admitted to ICU . as well asCompare causes and outcomes of sepsis between diabetics versus non diabetics . 3.Screening for the commonest organism causing sepsis in critically ill patients. Determine better protocol therapy that help in decreasing mortality and morbidity in patients with sepsis in ICU.

NCT ID: NCT03982628 Not yet recruiting - Sepsis Clinical Trials

ICU Sarcopenia Rates by Abdominal CT: Sepsis vs. Trauma

Start date: August 1, 2020
Phase:
Study type: Observational

Using abdominal computed tomography (CT) imaging, the investigators will estimate total body muscle mass at two time points in Intensive Care Unit (ICU) by assessing cross-sectional muscle areas at the L3 vertebral body level. This allows for a determination of the rate of sarcopenia development in the ICU. With this information, the investigators propose to test if the rates of the development of sarcopenia differ in critically ill subjects with sepsis compared to a reference group of critically ill subjects with trauma (without sepsis).

NCT ID: NCT03880305 Not yet recruiting - Neonatal Sepsis Clinical Trials

White Blood Cells and Platelets Indices as a Prognostic Factor in Neonatal Sepsis

Start date: April 1, 2019
Phase:
Study type: Observational [Patient Registry]

Sepsis is a complex condition initiated by a pathogen and mediated by cytokines followed by immune, inflammatory, and coagulation homeostasis disturbances, its evolution being dictated by a complicated balance between pro inflammatory and anti- inflammatory factors. Most of the short and long-term complications of the neonatal sepsis are strictly related to inflammatory mediators. Neonatal sepsis is associated with a mortality rate that ranges from 13 to 60% inspite of improved antibiotic therapy and an increased morbidity in survivors .

NCT ID: NCT03844542 Not yet recruiting - Sepsis Clinical Trials

Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE]

SAMOF-TPE
Start date: June 2019
Phase: N/A
Study type: Interventional

The investigators prospective, randomized adult clinical trial investigates the therapeutic efficacy of early therapeutic plasma exchange as adjunct treatment to standard therapy in patients with refractory septic shock and multiple organ failure.

NCT ID: NCT03842371 Not yet recruiting - Sepsis Syndrome Clinical Trials

Metabolism of Branched-chain Amino Acids in Monocyte/Macrophage During Sepsis

Start date: February 11, 2019
Phase:
Study type: Observational

The current project was designed to examine the metabolic level of branched-chain amino acids in plasm and monocyte/macrophage, and its role in immune dysfunction during sepsis.

NCT ID: NCT03837730 Not yet recruiting - Sepsis Clinical Trials

Citrulline and Arginase Activity in Severe Sepsis and Septic Shock

CARS
Start date: February 10, 2019
Phase:
Study type: Observational

Sepsis is an acute pathology defined as an inappropriate response of the host to infection, resulting in the onset of organ failure (Quick SOFA ≥2, or SOFA ≥2). Septic shock is a sepsis associated with an elevation of lactate ≥ 2 mmol / l and an arterial hypotension requiring vasoactive drugs. Several studies highlighted that sepsis is associated with a plasma L-arginine deficiency. This deficiency induces a lower availability of L-arginine for multiple metabolic pathways including those involved in the synthesis of nitric oxide (NO) in the vascular endothelium via NO synthase. NO is the main endogenous vasodilator mediator, a lower synthesis induces a vascular and endothelial dysfunction that can promote the occurrence of an organic dysfunction during sepsis. Decrease in available NO was confirmed in patients with sepsis and appears correlated with severity. L-arginine deficiency can have multiple origins: - L-arginine deficiency resulting from a decrease in endogenous production from citrulline synthesized by the enterocytes. Such enterocyte dysfunction has been confirmed in patients with sepsis and is characterized biologically by elevated plasma levels of I-FABP (intestinal fatty acid binding protein - enterocyte-specific protein, cytolysis marker) and lower than that of citrulline (hypocitrullinemia, marker of lower activity). - L-arginine deficiency may also result from a catabolism increase via arginase activity increased. This ubiquitous enzyme, having 2 isoforms (Arg1 and Arg2), allows the synthesis of urea and ornithine from L-arginine. An increase in arginase activity would decrease the available reserves of L-arginine for NO synthesis. The objectives of this work is to evaluate, in patients with severe sepsis or septic shock, the prognostic value of the plasma arginase activity and the plasma expression of 2 isoforms Arg1 and Arg2, their kinetics, and the link between activity / expression of arginase and enterocyte dysfunction.

NCT ID: NCT03795285 Not yet recruiting - Neonatal SEPSIS Clinical Trials

The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis

Start date: February 20, 2019
Phase:
Study type: Observational

Neonatal sepsis (NS) is a rather serious but relatively common health problem. Despite recent advances in the treatment of neonatal infection, mortality and comorbidities remain high.